{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee MK"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["2047-2058"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10241696"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(7)"],"pubmed_abstract":["Purpose
The standard recall period for the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) is the past 7 days, but there are contexts where a 24-hour recall may be desirable. The purpose of this analysis was to investigate the reliability and validity of a subset of PRO-CTCAE items captured using a 24-hour recall.Methods
27 PRO-CTCAE items representing 14 symptomatic adverse events (AEs) were collected using both a 24-hour recall (24 h) and the standard 7 day recall (7d) in a sample of patients receiving active cancer treatment (n = 113). Using data captured with a PRO-CTCAE-24h on days 6 and 7, and 20 and 21, we computed intra-class correlation coefficients (ICC); an ICC ≥ 0.70 was interpreted as demonstrating high test-"],"journal":["Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation"],"pubmed_title":["Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period."],"pmcid":["PMC10241696"],"funding_grant_id":["P30 CA008748","HHSN261200800043C","U01 CA233046"],"pubmed_authors":["Dueck AC","Mitchell SA","Mendoza TR","Minasian LM","Mazza GL","Schrag D","Ginos BF","Rogak LJ","Langlais BT","Basch E","Thanarajasingam G","Lee MK","Bennett AV"],"additional_accession":[]},"is_claimable":false,"name":"Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.","description":"Purpose
The standard recall period for the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) is the past 7 days, but there are contexts where a 24-hour recall may be desirable. The purpose of this analysis was to investigate the reliability and validity of a subset of PRO-CTCAE items captured using a 24-hour recall.Methods
27 PRO-CTCAE items representing 14 symptomatic adverse events (AEs) were collected using both a 24-hour recall (24 h) and the standard 7 day recall (7d) in a sample of patients receiving active cancer treatment (n = 113). Using data captured with a PRO-CTCAE-24h on days 6 and 7, and 20 and 21, we computed intra-class correlation coefficients (ICC); an ICC ≥ 0.70 was interpreted as demonstrating high test-","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-05-29T03:03:53.663Z","creation":"2025-02-19T02:38:12.101Z"},"accession":"S-EPMC10241696","cross_references":{"pubmed":["36897529"],"doi":["10.1007/s11136-023-03374-5"]}}